Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis

Show simple item record Sobral-Leite, Marcelo Wesseling, Jelle Smit, Vincent T H B M Nevanlinna, Heli van Miltenburg, Martine H Sanders, Joyce Hofland, Ingrid Blows, Fiona M Coulson, Penny Patrycja, Gazinska Schellens, Jan H M Fagerholm, Rainer Heikkilä, Päivi Aittomäki, Kristiina Blomqvist, Carl Provenzano, Elena Ali, Hamid R Figueroa, Jonine Sherman, Mark Lissowska, Jolanta Mannermaa, Arto Kataja, Vesa Kosma, Veli-Matti Hartikainen, Jaana M Phillips, Kelly-Anne Couch, Fergus J Olson, Janet E Vachon, Celine Visscher, Daniel Brenner, Hermann Butterbach, Katja Arndt, Volker Holleczek, Bernd Hooning, Maartje J Hollestelle, Antoinette Martens, John W M van Deurzen, Carolien H M van de Water, Bob Broeks, Annegien Chang-Claude, Jenny Chenevix-Trench, Georgia Easton, Douglas F Pharoah, Paul D P García-Closas, Montserrat de Graauw, Marjo Schmidt, Marjanka K 2015-07-03T03:42:21Z 2015-07-03T03:42:21Z 2015-07-02
dc.identifier.citation BMC Medicine. 2015 Jul 02;13(1):156
dc.description.abstract Abstract Background Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients. Methods Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical staining in tumor cells. Survival analyses were performed using a multivariable Cox model. Results The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P <0.0001. ANXA1 was also highly expressed in BCAC tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age. In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS) than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05–1.73), but the association weakened after 10 years (HRadj = 1.13; 95 % CI = 0.91–1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS: HRadj = 1.70; 95 % CI = 1.17–2.45). Conclusions ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.
dc.publisher BioMed Central
dc.title Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis 2015-07-03T03:42:21Z
dc.language.rfc3066 en
dc.rights.holder Sobral-Leite et al.

Files in this item

Total number of downloads: Loading...

Files Size Format View
12916_2015_Article_392.pdf 1.925Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record